Ebola whole virus vaccine shown effective, safe in primates
Friday, 27 March 2015
An Ebola whole virus vaccine, constructed using a novel experimental platform, has been shown to effectively protect monkeys exposed to the often fatal virus. The vaccine, described in the journal Science, was developed by a group led by Yoshihiro Kawaoka, a University of Wisconsin-Madison expert on avian influenza, Ebola and other viruses of medical importance.
AstraZeneca has joined a public-private consortium with Genomics England to accelerate the development of new diagnostics and treatments arising from the 100,000 Genomes Project. The GENE Consortium (Genomics Network for Enterprises Consortium) is a unique partnership between industry, academia and the National Health Service (NHS) Genomic Medicine Centres,
New MIND diet may significantly protect against Alzheimer's disease
Thursday, 26 March 2015
A new diet, appropriately known by the acronym MIND, could significantly lower a person's risk of developing Alzheimer's disease, even if the diet is not meticulously followed, according to a paper published online for subscribers in March in the journal Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
GSK's 2015 Discovery Fast Track Challenge seeks early drug discovery partnerships with academics in Europe, Canada and US
Thursday, 26 March 2015
GSK is encouraging academic scientists in Europe, Canada and the US to submit their novel early drug discovery research proposals into its third annual Discovery Fast Track Challenge - a programme designed to accelerate the translation of early-stage research into game-changing new medicines.
AstraZeneca to collaborate with the Harvard Stem Cell Institute in diabetes
Wednesday, 25 March 2015
AstraZeneca today announced that it has entered into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca's compound library in the search for new treatments for diabetes.
Bristol-Myers Squibb acquires exclusive license from Novo Nordisk for a discovery research program focused on autoimmune diseases
Tuesday, 24 March 2015
Bristol-Myers Squibb Company (NYSE:BMY) today announced the company has signed an agreement with Novo Nordisk under which Bristol-Myers Squibb will acquire an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases.
Pfizer and Lilly preparing to resume Phase 3 chronic pain program for Tanezumab
Monday, 23 March 2015
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement.